Creo que serán buenos, pero vete tú a saber qué considera bueno el mercado. Mira el palo que se está llevando CELG, con +13% en ventas, pelín por debajo de expectativas y un incremento en beneficios del 57% (!). Pues cotización -6.x%
¿Qué c... espera el mercado? ¿Crecimiento "hasta el infinito y mas allá? lo siento por ellos, tengo buenos amigos dentro y se lo frustrante que resulta hacerlo de PM para que 4 analistos te hundan...
Llevo mas de 3h con una orden de compra de ZALICUS a 1,05 y no me entra ... y me consta que ha estado a ese precio varias veces .... ummm.
Bueno, dentro de nuevo en ENDOCYTE a 7,05.
Jorge A me manda una alerta con esta empresa por si sabes algo de ella parece que los directivos estan comprando, gracias por constestarme ayer.Saludos
OPK - Insider Accumulation
http://finance.yahoo.com/q?s=opk&ql=1
Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico.
Opko Health, Inc. (OPK) -NYSE
4.83 0.05(1.02%) 4:00PM EDT|After Hours: 4.88 0.05 (1.04%) 4:03PM EDT - Nasdaq Real Time Price
Add to Portfolio
Analyst Opinion Get Analyst Opinion for:
Recommendation Summary*
Mean Recommendation (this week): 1.0
Mean Recommendation (last week): 1.0
Change: 0.0
* (Strong Buy) 1.0 - 5.0 (Sell)
Compare to Industry
Price Target Summary
Mean Target: 8.25
Median Target: 8.25
High Target: 8.50
Low Target: 8.00
No. of Brokers: 2
Data provided by Thomson/First Call
PUBLICIDAD
Upgrades & Downgrades History
No Upgrades & Downgrades available for OPK
Recommendation Trends
Current Month Last Month Two Months Ago Three Months Ago
Strong Buy 2 2 2 2
Buy 0 0 0 0
Hold 0 0 0 0
Underperform 0 0 0 0
Sell 0 0 0 0
Data provided by Thomson/First Call
Currency in USD.
Top Insider Trades 4/24/12: OPK, FRAN, PWON And GWRE
1-Descripción:
Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. It develops a range of solutions, including molecular diagnostics tests, point-of-care tests, and proprietary pharmaceuticals and vaccines to diagnose, treat, and prevent various conditions. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimers disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; and point-of-care diagnostic test for prostate specific antigen. It is also developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; vaccines using alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate, which has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. In addition, the company offers specialty active pharmaceutical ingredients in Israel; manufactures, markets, sells, and distributes ophthalmic and other pharmaceutical products in Mexico; and markets, sells, and distributes cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones in Chile. OPKO Health, Inc. was founded in 2006 and is based in Miami, Florida.
Vamos, que investigan ellos solos tanto como el NIH, Pfizer y J&J juntos...
2-Datos financieros básicos
Fiscal Year Ends: Dec 31
Most Recent Quarter (mrq): Dec 31, 2011
Profitability
Profit Margin (ttm): -4.59%
Operating Margin (ttm): -82.88%
Management Effectiveness
Return on Assets (ttm): -9.43%
Return on Equity (ttm): -5.51%
Income Statement
Revenue (ttm): 27.98M
Revenue Per Share (ttm): 0.10
Qtrly Revenue Growth (yoy): -52.60%
Gross Profit (ttm): 10.74M
EBITDA (ttm)6: -19.36M
Net Income Avl to Common (ttm): -8.84M
Diluted EPS (ttm): -0.01
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 71.52M
Total Cash Per Share (mrq): 0.24
Total Debt (mrq): 8.76M
Total Debt/Equity (mrq): 4.73
Current Ratio (mrq): 5.30
Book Value Per Share (mrq): 0.55
Cash Flow Statement
Operating Cash Flow (ttm): -18.50M
Levered Free Cash Flow (ttm): 2.18M
3 son claves: ventas 27.98M (para una compañía con un market cap de 1,43B, eso es peanuts), margen bruto -82.88%, EBITDA -19.36M
Si los insiders compran, allá ellos... :D
S2
Ok.Pasamos pagina,gracias
Jorge podrias interpretar algo sobre las noticias de ZLCS. Segun seeking alpha hay buenas noticias (hace 1 hora en google finance) y en pre market -4.6. La verdad es que no entiendo nada (la cosa no es que si hy buenas noticias la accion sube?
Framus, hoy vas a tener ZLCS a cerca de 1$
En pre esta a menos 4%
